Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 3
2009 6
2010 3
2011 7
2012 6
2013 1
2014 4
2015 8
2016 2
2017 5
2018 3
2019 6
2020 7
2021 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.
Kondo T, Jering KS, Jhund PS, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Packer M, Petrie MC, Pfeffer MA, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Solomon SD, McMurray JJV. Kondo T, et al. Circ Heart Fail. 2023 Jul;16(7):e010377. doi: 10.1161/CIRCHEARTFAILURE.122.010377. Epub 2023 Jun 23. Circ Heart Fail. 2023. PMID: 37350280 Clinical Trial.
BACKGROUND: The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without atrial fibrillation (AF), is uncertain as is whether it is possible to reliably predict the risk of stroke in these patients. METHODS: We val …
BACKGROUND: The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without a …
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C. Haynes R, et al. Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818. Circulation. 2018. PMID: 30002098 Free article. Clinical Trial.
BACKGROUND: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac biomarkers in people with moderate to severe chronic kidney d …
BACKGROUND: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients with heart failure with reduced …
Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
Kang H, Zhang J, Zhang X, Qin G, Wang K, Deng Z, Fang Y, Chen G. Kang H, et al. Eur J Pharmacol. 2020 Oct 5;884:173444. doi: 10.1016/j.ejphar.2020.173444. Epub 2020 Jul 30. Eur J Pharmacol. 2020. PMID: 32739172
Sacubitril/valsartan (LCZ696) is recommended for ejection fraction reduction in heart failure. However, studies comparing the effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease (CKD) with the inhibit …
Sacubitril/valsartan (LCZ696) is recommended for ejection fraction reduction in heart failure. However, studies …
Medical Therapies for Heart Failure With Preserved Ejection Fraction.
Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, Hopper I, Julius S, Pitt B, Reid CM, Devereux RB, Zannad F. Kjeldsen SE, et al. Hypertension. 2020 Jan;75(1):23-32. doi: 10.1161/HYPERTENSIONAHA.119.14057. Epub 2019 Dec 2. Hypertension. 2020. PMID: 31786973 Review.
Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs throughout the continuum of cardiovascular disease spanning from hypertension to heart failure with reduced ejection …
Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs t …
The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV, Desai AS, Givertz MM. Shah RV, et al. J Card Fail. 2010 Mar;16(3):260-7. doi: 10.1016/j.cardfail.2009.11.007. Epub 2010 Jan 6. J Card Fail. 2010. PMID: 20206902 Review.
BACKGROUND: Although renin-angiotensin system (RAS) inhibitors have little demonstrable effect on mortality in patients with heart failure and preserved ejection fraction (HF-PEF), some trials have suggested a benefit with regard to reduction in HF …
BACKGROUND: Although renin-angiotensin system (RAS) inhibitors have little demonstrable effect on mortality in patients with heart …
Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Massie BM, et al. N Engl J Med. 2008 Dec 4;359(23):2456-67. doi: 10.1056/NEJMoa0805450. Epub 2008 Nov 11. N Engl J Med. 2008. PMID: 19001508 Free article. Clinical Trial.
Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. ...There were no significant differences in the other prespecified outcomes. CON …
Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any …
Sex-Related Differences in Heart Failure With Preserved Ejection Fraction.
Dewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Dewan P, et al. Circ Heart Fail. 2019 Dec;12(12):e006539. doi: 10.1161/CIRCHEARTFAILURE.119.006539. Epub 2019 Dec 9. Circ Heart Fail. 2019. PMID: 31813280
BACKGROUND: To describe characteristics and outcomes in women and men with heart failure with preserved ejection fraction. METHODS: Baseline characteristics (including biomarkers and quality of life) and outcomes (primary outcome: composite of first …
BACKGROUND: To describe characteristics and outcomes in women and men with heart failure with preserved ejection fra …
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction.
McDowell K, Kondo T, Talebi A, Teh K, Bachus E, de Boer RA, Campbell RT, Claggett B, Desai AS, Docherty KF, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Simpson J, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. McDowell K, et al. JAMA Cardiol. 2024 Mar 27:e240284. doi: 10.1001/jamacardio.2024.0284. Online ahead of print. JAMA Cardiol. 2024. PMID: 38536153
IMPORTANCE: Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF) may help clinicians risk stratify and inform care decisions. ...DESIGN, SETTING, AND PARTICIPANTS: Data were used fr …
IMPORTANCE: Accurate risk prediction of morbidity and mortality in patients with heart failure with preserved ejection …
Canagliflozin Ameliorates Ventricular Remodeling through Apelin/Angiotensin-Converting Enzyme 2 Signaling in Heart Failure with Preserved Ejection Fraction Rats.
Zhang T, Wang X, Wang Z, Zhai J, He L, Wang Y, Zuo Q, Ma S, Zhang G, Guo Y. Zhang T, et al. Pharmacology. 2023;108(5):478-491. doi: 10.1159/000533277. Epub 2023 Aug 23. Pharmacology. 2023. PMID: 37611563 Free article.
INTRODUCTION: The aim of this study was to investigate the effect of canagliflozin (CANA) on ventricular remodeling in patients with preserved ejection fraction (HFpEF) heart failure and to further investigate its possible molecular mechanisms. METHODS …
INTRODUCTION: The aim of this study was to investigate the effect of canagliflozin (CANA) on ventricular remodeling in patients with preserv …
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?
Oghlakian GO, Sipahi I, Fang JC. Oghlakian GO, et al. Mayo Clin Proc. 2011 Jun;86(6):531-9. doi: 10.4065/mcp.2010.0841. Epub 2011 May 16. Mayo Clin Proc. 2011. PMID: 21576513 Free PMC article. Review.
Heart failure with preserved ejection fraction (HF-PEF) is the clinical syndrome of heart failure associated with normal or near-normal systolic function. Because inhibition of the adrenergic and renin-angiotensin-aldosterone systems has …
Heart failure with preserved ejection fraction (HF-PEF) is the clinical syndrome of heart failure …
60 results